Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,